The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.
John C. Byrd
Research Funding - Pharmacyclics
Richard R. Furman
Research Funding - Pharmacyclics
Steven E. Coutre
Research Funding - Pharmacyclics
Jan Andreas Burger
Research Funding - Pharmacyclics
Kristie A. Blum
Research Funding - Pharmacyclics
Jeff Porter Sharman
Research Funding - Pharmacyclics
Ian W. Flinn
Research Funding - Pharmacyclics
Barbara W. Grant
Research Funding - Pharmacyclics
Nyla A. Heerema
No relevant relationships to disclose
Amy J Johnson
No relevant relationships to disclose
Tasheda Navarro
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Danelle Frances James
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Eric Hedrick
Employment or Leadership Position - Pharmacyclics
Stock Ownership - Pharmacyclics
Susan Mary O'Brien
Research Funding - Pharmacyclics